• Targeting CK2 and Cellular Senescence: Ellagic Acid as a ...

  2025-10-23

  This thought-leadership article explores the mechanistic promise and translational opportunities of Ellagic acid—a selective, ATP-competitive casein kinase 2 (CK2) inhibitor with robust antioxidant and antitumor properties. The piece synthesizes recent advances in senescence research, competitive compound discovery, and AI-driven drug screening, offering strategic guidance for researchers investigating cancer biology, oxidative stress pathways, and apoptosis. By highlighting how Ellagic acid enables nuanced interrogation of CK2 signaling and tumor suppression, the article provides actionable insights for translational teams seeking to harness the next wave of targeted therapeutics.

• AT-406 (SM-406): Unraveling IAP Inhibition and Apoptosis ...

  2025-10-22

  Discover how AT-406 (SM-406), a potent IAP inhibitor, uniquely illuminates the intersection of apoptosis pathway activation and therapeutic innovation in cancer research. This article provides fresh mechanistic insight, explores advanced applications, and positions AT-406 at the cutting edge of translational oncology.

• WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Me...

  2025-10-21

  WY-14643 (Pirinixic Acid) is redefining metabolic and tumor microenvironment research by enabling precise modulation of PPARα and PPARγ pathways. Its potent, selective activity and proven anti-inflammatory and insulin-sensitizing effects make it an indispensable tool for dissecting lipid metabolism and TNF-α mediated inflammation in both basic and translational studies.

168 records 12/12 page Previous First page 上5页 1112